A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
Shibani Nicum(London Cancer), Susan Dutton(Oxford Centre for Diabetes, Endocrinology and Metabolism), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Lucy Boyle(University of Oxford), Linda Collins(University of Oxford), Sylwia Kopijasz(University of Oxford), Anna Schuh(University of Oxford), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Charlie Gourley(Edinburgh Cancer Research), Christopher Poole(Guy's Hospital), Corran Roberts(Nuffield Orthopaedic Centre)
Cited by 10
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k